Bidness ETC FDA Advisory votes against approving Actavis nebivolol/valsartan combo The Pharma Letter Nebivolol (marketed in the USA as Bystolic by Actavis subsidiary Forest Labs) is indicated for the treatment of hypertension and is effective at… Source: http://www.thepharmaletter.com See on Scoop.it – Cardiotoxicity
Search Results for 'Nebivolol'
FDA Advisory votes against approving Actavis nebivolol/valsartan combo – The Pharma Letter
Posted in Uncategorized on September 12, 2014| Leave a Comment »
Top Articles by Number of e-Readers for All Days ending 2019-02-17
Posted in on February 17, 2019|
Top Articles by Number of e-Readers for All Days ending 2019-02-17 (Summarized) All Time Title Views Home page / Archives 603,640 Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 16,748 Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,287 Paclitaxel vs […]
Dynamic Contents for LPBI Group’s PowerPoint Presentation
Posted in on February 17, 2019|
Dynamic Contents for LPBI Group’s PowerPoint Presentation The source material used in the creation of LPBI Group’s PowerPoint Presentation is from Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/ WORK-in-PROGRESS Challenges and Opportunities for […]
Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com
Posted in Academic Publishing, Big Data & Analytics, Curation, Curation methodology, De novo synthesis, Dialectic, Discovery process, Evolutionary cognition, Experimental validation, Explanatory, Historical relevance, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Open Access Journals, Scientific Publishing, Scientist: Career considerations, Technology Advance Assessment of, Theoretic convergence on January 30, 2019| Leave a Comment »
Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com Reporter: Aviva Lev-Ari, PhD, RN Expert, Author, Writer’s Initials Name & Bio Roles @LPBI Group LHB Larry Bernstein, MD, FACP, Member of the Board Expert, Author, Writer – All Specialties of Medicine & Pathology Content Consultant to Series B,C,D,E Editor, Series […]
Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN
Posted in LPBI Group Founder - Aviva Lev-Ari on October 21, 2018| Leave a Comment »
Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN March 31, 2018 Yidan Prize for Education Development recognizes innovative ideas that tackle pressing challenges in the field of education. Nomination for recognition as means in tackling challenges […]
Data Science is the Greatest Science! It is the Greatest Science for Women, as well
Posted in Big Data & Analytics, Data Science, Scientist: Career considerations, Women in Life Sciences on March 12, 2018| Leave a Comment »
Data Science is the Greatest Science! It is the Greatest Science for Women, as well Curator: Aviva Lev-Ari, PhD, RN UPDATED ON 3/2/2018 The Growing Influence of Analytics on the C-Suite This curation has three parts: Part 1: Account of a Data Scientist, Aviva Lev-Ari, PhD – worked in Data Science, 1976-2005 […]
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
Posted in Award Nominations, LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on March 6, 2018| 5 Comments »
Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018 Prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section. The profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/ Excerpts were Published in AFHU e-news on 5/11/2018. https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72 https://www.afhu.org/2018/05/03/aviva-lev-ari/ Aviva Lev-Ari, PhD, RN – February […]
Updated on 4/14/2019 –>> FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018
Posted in LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on April 28, 2017| Leave a Comment »
Updated on 4/14/2019 –>> FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018 UPDATED on 4/14/2019 Top Posts for all days ending 2019-04-14 (Summarized) All Time Title Views Home page / Archives 615,383 Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century […]